医学
放射外科
脑转移
不利影响
外科
人口
脑瘤
肿瘤进展
转移
无进展生存期
死因
生活质量(医疗保健)
病历
前瞻性队列研究
放射治疗
中枢神经系统疾病
死亡率
远处转移
存活率
作者
Eleanor Cecile Smith,Bryan T. Mott,Jared M. Kaplan,Carol Kittel,Molly R Ehrig,Christina Kehl Cramer,Jaclyn White,Stephen B. Tatter
出处
期刊:Research Square
日期:2026-09-11
标识
DOI:10.21203/rs.3.rs-10780474/v1
摘要
Abstract PURPOSE Brain metastases affect many patients with solid tumor malignancies. Treatments include surgery, radiation, immunotherapy, and CNS-penetrating chemotherapy. Nonetheless rates of neurologic death remain high. Local recurrence after radiosurgery and tumors too large for radiosurgery present a particular challenge. The VIGILANT (Vigilant Observation of GLIADEL Wafer Implant) registry prospectively examines use and efficacy of carmustine-releasing, wafers including in patients with brain metastases. Here we present results of patients with brain metastasis from the VIGILANT registry. METHODS Forty-eight patients were observed after surgical resection of brain metastasis and GLIADEL implantation at Wake Forest Baptist Medical Center. Thirty-three patients underwent treatment for local recurrence following radiosurgery. Fifteen had lesions deemed too large for successful radiosurgery. Patients were evaluated primarily for overall survival (OS) and progression free survival (PFS) from date of surgery, and secondarily for adverse events and local progression. RESULTS Median OS was 14.9 months (95% CI 8.3, 26.0). Of 25 deaths, 7 (28%) met criteria for neurological etiology. Twenty-seven (56%) patients had progression during follow up, Six (12.5%) had local progression. Two (4%) had local progression that required additional neurosurgical treatment. Of 15 patients not previously treated with radiosurgery, 8 (53%) had no progression. Forty-three patients had adverse events; two considered possibly GLIADEL related. CONCLUSIONS Treatment of brain metastases too large for radiosurgery or that failed initial radiosurgery with carmustine-releasing wafers was associated with favorable OS (14.9 months) and 1-year local progression rate (12%) in this very challenging population and was well tolerated.
科研通智能强力驱动
Strongly Powered by AbleSci AI